Event will showcase results of Company's
pivotal PRIME study and include the principal
investigator
SALT
LAKE CITY, Jan. 27, 2025 /PRNewswire/ -- Sera
Prognostics Inc., The Pregnancy Company®
(NASDAQ: SERA), focused on improving maternal and neonatal health
by providing innovative pregnancy biomarker information to doctors
and patients, today announced that it plans to host a virtual
R&D day on January 31, 2025, from
5:00 to 6:00 p.m. ET/2:00 to 3:00 p.m. PT. This date was changed from
the prior planned date of the event due to scheduling
conflicts.
During the event, Sera's management team, and principal
investigator for the Company's pivotal PRIME study, Dr. Brian
Iriye, maternal-fetal medicine expert at the High-Risk Pregnancy
Center in Las Vegas, Nevada,
will present results of the Prematurity Risk
Assessment Combined With Clinical Interventions for
Improving Neonatal outcoMEs ("PRIME") study and answer
questions regarding this pivotal research.
Conference Call Information
Sera Prognostics will host a corresponding conference call and
live webcast of the R&D day on January
31 from 5:00-6:00 p.m.
ET/2:00-3:00 p.m. PT.
Individuals interested in listening to the conference call may do
so by dialing the following:
US domestic callers: (800) 836-8184
International callers: (646) 357-8785
Webcast Registration Link:
https://app.webinar.net/AZp49gQPVbM
Live audio of the webcast will be available online from the
Investors page of the Company's website https://www.sera.com/. The
webcast will be archived on the Investors page and will be
available for one year.
About Sera Prognostics, Inc.
Sera Prognostics is a leading health diagnostics company
dedicated to improving the lives of women and babies through
precision pregnancy care. Sera's mission is to provide early,
pivotal pregnancy information to improve the health of mothers and
newborns, resulting in reductions in the costs of healthcare
delivery. Sera has a robust pipeline of innovative diagnostic tests
focused on the early prediction of preterm birth risk and other
complications of pregnancy. Sera's precision medicine PreTRM® Test
reports to a physician the individualized risk of spontaneous
premature delivery in a pregnancy, enabling earlier proactive
interventions in women with higher risk. Sera Prognostics is
headquartered in Salt Lake City, Utah.
About Preterm Birth
Preterm birth is defined as any birth before 37 weeks' gestation
and is the leading cause of illness and death in newborns. The 2023
March of Dimes Report Card shows that, for the last five
consecutive years, more than one in ten infants is born prematurely
in the United States. Prematurity
is associated with a significantly increased risk of major
long-term medical complications, including learning disabilities,
cerebral palsy, chronic respiratory illness, intellectual
disability, seizures, and vision and hearing loss, and can generate
significant costs throughout the lives of affected children. The
annual health care costs to manage short- and long-term
complications of prematurity in the United States were
estimated to be approximately $25 billion for 2016.
About the PreTRM® Test
The PreTRM® Test is the only broadly validated,
commercially available blood-based biomarker test that provides an
early, accurate and individualized risk prediction for spontaneous
preterm birth in asymptomatic singleton pregnancies. The
PreTRM® Test measures and analyzes proteins in the blood
that are highly predictive of preterm birth. The PreTRM®
Test permits physicians to identify, during the weeks 18 through 20
of pregnancy, which women are at increased risk for preterm birth
and its complications, enabling more informed, personalized
clinical decisions based on each woman's individual risk. The
PreTRM® Test is ordered by a medical professional.
Sera Prognostics, the Sera Prognostics logo, The Pregnancy
Company, and PreTRM are trademarks or registered trademarks of Sera
Prognostics, Inc. in the United States and/or other
countries.
Safe Harbor Statement
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements relating to the date, time, content and
webcast replay availability of the Company's R&D day; and the
company's strategic directives under the caption "About Sera
Prognostics, Inc." These "forward-looking statements" are based on
management's current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in
or implied by forward-looking statements. These risks and
uncertainties include, but are not limited to: net losses, cash
generation, and the potential need to raise more capital; revenues
from the PreTRM Test representing substantially all Company
revenues to date; the need for broad scientific and market
acceptance of the PreTRM Test; a concentrated number of material
customers; our ability to introduce new products; potential
competition; our proprietary biobank; critical suppliers; the
COVID-19 pandemic and its potential lingering impact on our
operations, as well as the business or operations of third parties
with whom we conduct business; estimates of total addressable
market opportunity and forecasts of market growth; potential
third-party payer coverage and reimbursement; new reimbursement
methodologies applicable to the PreTRM Test, including new CPT
codes and payment rates for those codes; changes in FDA regulation
of laboratory-developed tests; the intellectual property rights
protecting our tests and market position; and other factors
discussed under the heading "Risk Factors" contained in our Annual
Report on Form 10-K and Quarterly Reports on Form 10-Q filed with
the Securities and Exchange Commission, as well as any updates to
those risk factors filed from time to time in our periodic and
current reports filed with the Securities and Exchange Commission.
All information in this press release is as of the date of the
release, and the Company undertakes no duty to update this
information unless required by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sera-prognostics-to-host-virtual-rd-day-on-january-31-302361294.html
SOURCE Sera Prognostics, Inc.
